ATRA
Atara Biotherapeutics, Inc.
$9.77
+1.98%
$86.3M
No data for this timeframe.
Vol
Market Cap$86.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders6 funds
Inst. Value$5.4M
Inst. Activity2 buys / 1 sells
Insider Activity1B / 5S
Insider Net $$1.5M
SEC Reports7
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001604464·Prev Close $9.58
Recent Activity
May 18, 2026
Insider
Grant-Huerta Yanina sold 2,414 shares
Chief Accounting Officer @ $9.13 ($22.0K)
May 18, 2026
Insider
Nguyen AnhCo sold 5,241 shares
President and CEO @ $9.13 ($47.8K)
May 13, 2026
earnings_calendar
ATRA Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
SEC
Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of shares, while director
CLUSTER — Impact 5/10
May 7, 2026
SEC
Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study with an appropriate h
8-K — Impact 4/10
May 7, 2026
Insider
EcoR1 Capital, LLC bought 507,407 shares
10%+ Owner @ $9.35 ($4.7M)
Apr 24, 2026
SEC
Atara Biotherapeutics is holding its 2026 annual meeting to vote on four key proposals: electing two directors, approvin
DEFA14A — Impact 3/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
30,040 shares ($543.4K)
Price Targets
$13.67
+39.9% upside
Strong Buy
Current $9.77
Low $10.00
Median $13.00
High $18.00
3 analysts
$10.00
$18.00
Analyst Ratings
2Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | Freedom Broker | UPGRADE | Sell → Hold |
| May 8, 2026 | Canaccord Genuity | UPGRADE | Hold → Buy |
| Jan 21, 2026 | Freedom Broker | DOWNGRADE | Buy → Sell |
| Jan 13, 2026 | Canaccord Genuity | DOWNGRADE | Buy → Hold |
| Dec 19, 2025 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.35 ▼ -183.8% | $-0.35 — $-0.35 | -284% YoY | 1 |
| Next Q | $-0.30 ▼ -1185.9% | $-0.30 — $-0.30 | 6% YoY | 1 |
| Current FY | $-1.23 ▼ -329.1% | $-1.23 — $-1.23 | -148% YoY | 1 |
| Next FY | $1.64 ▲ +102.1% | $0.20 — $3.70 | 233% YoY | 3 |
Latest Reports
MIXED
CLUSTER
5/10
Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of shares, while director
May 11, 2026
NEUTRAL
8-K
4/10
Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study with an appropriate h
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $4.1M | — |
| RENAISSANCE TECHNOLOGIES LLC | $543.4K | ADD |
| FMR LLC | $310.4K | TRIM |
| MORGAN STANLEY | $289.3K | TRIM |
| BANK OF AMERICA CORP | $187.9K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Grant-Huerta Yanina | SELL | $22.0K |
| May 18, 2026 | Nguyen AnhCo | SELL | $47.8K |
| May 7, 2026 | EcoR1 Capital, | BUY | $4.7M |
| May 7, 2026 | Panacea Innovation | SELL | $3.2M |
| Mar 17, 2026 | Panacea Innovation | M | $25.92 |
6 institutional holders with $5.4M total value (299,765 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, FMR. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 225,940 | $4.1M | 75.4% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 30,040 | $543.4K | 10.0% | ADD +58.6% |
| 3 | FMR LLC | 17,156 | $310.4K | 5.7% | TRIM -35.7% |
| 4 | MORGAN STANLEY | 15,991 | $289.3K | 5.3% | TRIM -55.5% |
| 5 | BANK OF AMERICA CORP /DE/ | 10,387 | $187.9K | 3.5% | ADD +77.7% |
| 6 | WELLS FARGO & COMPANY/MN | 251 | $4.5K | 0.1% | TRIM -73.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 18,936 | 30,040 | +58.6% | $543.4K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 35,938 | 15,991 | -55.5% | $289.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 5,845 | 10,387 | +77.7% | $187.9K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 14,926 | 35,938 | +140.8% | $515.0K | 2025-Q3 |
| UBS Group AG | DOUBLED | 8,385 | 17,268 | +105.9% | $247.5K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 951 | 251 | -73.6% | $3.6K | 2025-Q3 |
| MORGAN STANLEY | ADD | 11,828 | 14,926 | +26.2% | $115.2K | 2025-Q2 |
| UBS Group AG | TRIM | 24,334 | 8,385 | -65.5% | $64.7K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 187,297 | 7,688 | -95.9% | $59.4K | 2025-Q2 |
| UBS Group AG | DOUBLED | 834 | 24,334 | +2817.7% | $144.5K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 67,140 | 17,436 | -74.0% | $103.6K | 2025-Q1 |
| FMR LLC | TRIM | 26,699 | 17,157 | -35.7% | $101.9K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 28,351 | 11,828 | -58.3% | $70.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 267,353 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 16,189 | 28,351 | +75.1% | $377.4K | 2024-Q4 |
| UBS Group AG | DOUBLED | 402 | 834 | +107.5% | $11.1K | 2024-Q4 |
| MORGAN STANLEY | ADD | 9,785 | 16,189 | +65.4% | $131.6K | 2024-Q3 |
4 unique insiders with 6 transactions. Net insider value: $1.5M ($4.7M bought, $3.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Grant-Huerta Yanina | Chief Accounting Officer | SELL | 2,414 | $9.13 | $22.0K |
| May 18, 2026 | Nguyen AnhCo | President and CEO | SELL | 5,241 | $9.13 | $47.8K |
| May 7, 2026 | EcoR1 Capital, LLC | 10%+ Owner | BUY | 507,407 | $9.35 | $4.7M |
| May 7, 2026 | Panacea Innovation Ltd | Director | SELL | 313,446 | $10.10 | $3.2M |
| Mar 17, 2026 | Panacea Innovation Ltd | Director | M | 259,163 | $0.000100 | $25.92 |
| Mar 17, 2026 | Panacea Innovation Ltd | Director | M | 259,163 | $6.61 | $1.7M |
| Mar 17, 2026 | Panacea Innovation Ltd | Director | F | 5 | $5.23 | $26.15 |
| Mar 9, 2026 | Grant-Huerta Yanina | Chief Accounting Officer | A | 20,300 | $0.00 | $0.00 |
| Mar 9, 2026 | Nguyen AnhCo | President and CEO | A | 81,100 | $0.00 | $0.00 |
| Mar 2, 2026 | Nguyen AnhCo | President and CEO | SELL | 198 | $5.08 | $1.0K |
| Mar 2, 2026 | Grant-Huerta Yanina | Chief Accounting Officer | SELL | 24 | $5.08 | $121.85 |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 5 neutral. Avg impact: 4.1/10.
MIXED
CLUSTER
5/10
Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of sh
May 11, 2026
NEUTRAL
8-K
4/10
Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study w
May 7, 2026
NEUTRAL
DEFA14A
3/10
Atara Biotherapeutics is holding its 2026 annual meeting to vote on four key proposals: electing two
Apr 24, 2026
NEUTRAL
S-3
4/10
Atara Biotherapeutics has filed an S-3 shelf registration to register 400,000 shares of common stock
Mar 17, 2026
NEUTRAL
8-K
5/10
Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the
Mar 12, 2026
NEUTRAL
CLUSTER
2/10
Two insiders at Atara Biotherapeutics sold shares in the past week, including CEO AnhCo Nguyen who s
Mar 4, 2026
MIXED
8-K
6/10
Atara Biotherapeutics announced that its partner Pierre Fabre Pharmaceuticals has requested a Type A
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (80% buy). Based on 10 analysts: 2 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.67 mean target
+39.9% upside
Strong Buy (3.00)
$10.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $9.77 |
| Target Low | $10.00 |
| Target Mean | $13.67 |
| Target Median | $13.00 |
| Target High | $18.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.35 | $-0.35 | $-0.35 | -284.2% | -183.8% | — | $0.0B | -99.7% | 1 |
| Next Q 2026-09-30 |
$-0.30 | $-0.30 | $-0.30 | 6.3% | -1185.9% | — | $0.0B | -98.6% | 1 |
| Current FY 2026-12-31 |
$-1.23 | $-1.23 | $-1.23 | -147.9% | -329.1% | 0↑ 1↓ | $0.0B | -99.5% | 1 |
| Next FY 2027-12-31 |
$1.64 | $0.20 | $3.70 | 233.1% | +102.1% | 1↑ 0↓ | $0.1B | 7700.1% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.350 | |
| 7d ago | $-0.123 | -0.227 |
| 30d ago | $-0.123 | -0.227 |
| 60d ago | $-0.040 | -0.310 |
| 90d ago | $-0.570 | +0.220 |
2 analyst firms have rated this stock: 2 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | Freedom Broker | UPGRADE | Sell | Hold |
| May 8, 2026 | Canaccord Genuity | UPGRADE | Hold | Buy |
| Jan 21, 2026 | Freedom Broker | DOWNGRADE | Buy | Sell |
| Jan 13, 2026 | Canaccord Genuity | DOWNGRADE | Buy | Hold |
| Dec 19, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 2 | 5 | 2 | 1 | 0 | 70% | |
| Apr 1, 2026 | 2 | 5 | 2 | 1 | 0 | 70% | |
| Mar 1, 2026 | 2 | 5 | 3 | 1 | 0 | 64% | |
| Feb 1, 2026 | 0 | 1 | 4 | 2 | 2 | 11% | |
| Jan 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
ATRA Q1 2026 Earnings Scheduled — 2026-05-13
May 8, 2026
short_interest
FTD: ATRA — 78,159 shares ($0.8M) failed to deliver
Settlement: 20260508, Price: $9.93, FTD Value: $776,118.87, ATARA BIOTHERAPEUTICS INC COM
May 7, 2026
short_volume
Short Volume: ATRA — 58.8% short (20.7M / 35.1M)
Short: 20,652,044 | Exempt: 189,190 | TRF Vol: 35,115,186 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
ATRA Q1 2026 Earnings Scheduled — 2026-05-06
Mar 2, 2026
earnings_calendar
ATRA Q4 2025 Earnings After Market Close — 2026-03-02
Jan 10, 2026
fda_pdufa
PDUFA: ATRA — tab-cel in Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) — 2026-01-10
FDA target action date 2026-01-10 for ATRA (Atara Biotherapeutics, Inc.). Drug: tab-cel. Indication: Epstein-Barr virus positive post-transplant lymph